

Ming Y Lim

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/99711/publications.pdf>

Version: 2024-02-01

72
papers

617
citations

840119

11
h-index

713013

21
g-index

72
all docs

72
docs citations

72
times ranked

807
citing authors

#	ARTICLE	IF	CITATIONS
1	Budget Impact of Emicizumab for Routine Prophylaxis of Bleeding Episodes in Patients With Hemophilia A With Inhibitors. <i>Value in Health Regional Issues</i> , 2022, 28, 7-13.	0.5	2
2	Off-label use of emicizumab in persons with acquired haemophilia A and von Willebrand disease: A scoping review of the literature. <i>Haemophilia</i> , 2022, 28, 4-17.	1.0	20
3	36-year-old male with linked congenital sideroblastic anemia presenting as chronic microcytic anemia with iron overload. <i>International Journal of Laboratory Hematology</i> , 2022, 44, 69-71.	0.7	2
4	Optimizing Thromboembolism Prophylaxis for the Contemporary Age of Multiple Myeloma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 91-95.	2.3	9
5	Update on Guidelines for the Prevention of Cancer-Associated Thrombosis. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, , 1-8.	2.3	6
6	Race, rituximab, and relapse in TTP. <i>Blood</i> , 2022, 140, 1335-1344.	0.6	13
7	Management of inhibitors in persons with non-severe hemophilia A in the United States. <i>American Journal of Hematology</i> , 2021, 96, E9-E11.	2.0	4
8	Acquired von Willebrand syndrome in monoclonal gammopathy – A scoping review on hemostatic management. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, 356-365.	1.0	18
9	Daratumumab as a novel treatment for refractory acquired von Willebrand syndrome associated with monoclonal gammopathy. <i>Haemophilia</i> , 2021, 27, e563-e566.	1.0	4
10	Vaccine-induced thrombotic thrombocytopenia following Ad26.COV2.S vaccine in a man presenting as acute venous thromboembolism. <i>American Journal of Hematology</i> , 2021, 96, E346-E349.	2.0	19
11	Characteristics and outcomes of patients on concurrent direct oral anticoagulants and targeted anticancer therapies – TacDOAC registry: Communication from the ISTH SSC Subcommittee on Hemostasis and Malignancy. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2068-2081.	1.9	23
12	Disorders of Fibrinogen and Fibrinolysis. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 1197-1217.	0.9	16
13	Concomitant use of combined hormonal contraceptives and antifibrinolytic agents for the management of heavy menstrual bleeding: A practice pattern survey. <i>Thrombosis Research</i> , 2021, 204, 95-100.	0.8	1
14	Evaluation of ISTH-BAT as a predictor for factor deficiency in haemophilia carriers: a single-centre experience. <i>Blood Coagulation and Fibrinolysis</i> , 2021, 32, 611-613.	0.5	2
15	Left atrial appendage occlusion for management of atrial fibrillation in persons with hemophilia. <i>Thrombosis Research</i> , 2021, 206, 9-13.	0.8	8
16	A Descriptive Analysis of Immune Thrombotic Thrombocytopenic Purpura (iTTP) Patients with Fatal Outcomes in the U.S. Thrombotic Microangiopathy (USTMA) TTP Registry. <i>Blood</i> , 2021, 138, 4227-4227.	0.6	0
17	Preferences for Accessing Patient Reported Outcomes and Health Information Among Thrombotic Thrombocytopenic Purpura Survivors. <i>Blood</i> , 2021, 138, 3039-3039.	0.6	0
18	Evidence-Based Minireview: For overweight or obese persons with hemophilia A, should factor VIII dosing be based on ideal or actual body weight?. <i>Hematology American Society of Hematology Education Program</i> , 2021, 2021, 215-218.	0.9	1

#	ARTICLE	IF	CITATIONS
19	How do we optimally utilize factor concentrates in persons with hemophilia?. Hematology American Society of Hematology Education Program, 2021, 2021, 206-214.	0.9	4
20	How to Choose An Appropriate Anticoagulant for Cancer-Associated Thrombosis. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 1203-1210.	2.3	3
21	Impact of Benign Hematology Didactic Lectures on In-service Exam in a Hematology-Oncology Fellowship Program: a Cross-sectional Longitudinal Study. Journal of Cancer Education, 2020, 35, 705-708.	0.6	2
22	Impact of the Hemostasis and Thrombosis Research Society trainee workshop in recruiting the next generation of nonmalignant hematologists. Journal of Thrombosis and Thrombolysis, 2020, 49, 451-456.	1.0	0
23	Successful Management of Thrombotic Thrombocytopenic Purpura in a Jehovah's Witness: An Individualized Approach With Joint Decision-Making. Journal of Patient Experience, 2020, 7, 8-11.	0.4	7
24	Periprocedural use of avatrombopag for neurosurgical interventions: a strategy to avoid platelet utilization. Blood Advances, 2020, 4, 4438-4441.	2.5	3
25	Nonsevere hemophilia A: often overlooked, but not forgotten. Current Opinion in Hematology, 2020, 27, 295-301.	1.2	0
26	Inhibitors and mortality in persons with nonsevere hemophilia A in the United States. Blood Advances, 2020, 4, 4739-4747.	2.5	4
27	Systems-based hematology: highlighting successes and next steps. Blood Advances, 2020, 4, 4574-4583.	2.5	8
28	Leukocytoclastic vasculitis in T-cell lymphoma. Clinical Case Reports (discontinued), 2020, 8, 3630-3631.	0.2	0
29	Things We Do for No Reason ^{â„¢} : Routinely Prescribing Transfusion Premedication to Prevent Acute Transfusion Reactions. Journal of Hospital Medicine, 2020, 15, 684-686.	0.7	1
30	High prevalence of overweight/obesity in adult persons with hemophilia in Utah and a review of the literature. Blood Coagulation and Fibrinolysis, 2020, 31, 522-529.	0.5	8
31	Prolonged Remission of Cancer of Unknown Primary following Initiation of Eculizumab Therapy for Paroxysmal Nocturnal Hemoglobinuria. Case Reports in Hematology, 2019, 2019, 1-3.	0.3	1
32	Parvovirus B19-induced hemophagocytic lymphohistiocytosis: Case report and review of the literature. Clinical Case Reports (discontinued), 2019, 7, 2076-2081.	0.2	8
33	Outcomes of Using IVC Filters in Patients with Malignancy at an Academic Medical Center. TH Open, 2019, 03, e117-e122.	0.7	4
34	Importance of platelet activation in the regulation of whole blood coagulation in the presence of a factor V inhibitor. Haemophilia, 2019, 25, e307-e310.	1.0	0
35	Limited impact of clinician education on reducing inappropriate PF4 testing for heparin-induced thrombocytopenia. Journal of Thrombosis and Thrombolysis, 2019, 47, 287-291.	1.0	6
36	An under-recognized cause of copper deficiency mimicking myelodysplastic syndrome. Annals of Hematology, 2019, 98, 1021-1023.	0.8	0

#	ARTICLE	IF	CITATIONS
37	Analyzing the impact of systems-based hematologist in the healthcare system at an academic medical center. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 47, 109-112.	1.0	1
38	All-Cause and Inhibitor-Related Mortality in Non-Severe Hemophilia \hat{r} Patients in the United States. <i>Blood</i> , 2019, 134, 902-902.	0.6	2
39	Differential Effect of Rituximab on Relapse-Free Survival in De Novo and Relapsed Immune Thrombotic Thrombocytopenic Purpura in African-American and Caucasian Populations. <i>Blood</i> , 2019, 134, 90-90.	0.6	2
40	Pharmacoeconomic Analysis of Ideal Vs. Actual Body Weight-Based Treatment for Adult Persons with Hemophilia \hat{r} . <i>Blood</i> , 2019, 134, 4684-4684.	0.6	0
41	African American Race Is Associated with Decreased Relapse-Free Survival in Immune Thrombotic Thrombocytopenic Purpura. <i>Blood</i> , 2019, 134, 1066-1066.	0.6	2
42	Inpatient thrombophilia testing: Impact of healthcare system technology and targeted clinician education on changing practice patterns. <i>Vascular Medicine</i> , 2018, 23, 78-79.	0.8	6
43	Initial and long term impact of a multi-disciplinary task force in the diagnosis and management of heparin-induced thrombocytopenia. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 45, 130-134.	1.0	8
44	Practice Patterns of Inferior Vena Cava Filter Placement and Factors That Predict Retrieval Rates: A Single-Center Institution and Review of the Literature. <i>Journal of Clinical Medicine Research</i> , 2018, 10, 758-764.	0.6	6
45	Limited Impact of Clinician Education on Reducing Inappropriate PF4 Testing for Heparin-Induced Thrombocytopenia. <i>Blood</i> , 2018, 132, 827-827.	0.6	0
46	Radionuclide synovectomy in patients with bleeding disorders: a review of malignancy and myeloproliferative neoplasms from the $\langle \text{scp} \rangle$ ATHN $\langle / \text{scp} \rangle$ dataset. <i>Haemophilia</i> , 2017, 23, e160-e162.	1.0	4
47	Radionuclide synovectomy/synoviorthesis ($\langle \text{scp} \rangle$ RS $\langle / \text{scp} \rangle$) in persons with bleeding disorders: A review of impact of national guidance on frequency of $\langle \text{scp} \rangle$ RS $\langle / \text{scp} \rangle$ using the ATHN dataset. <i>Haemophilia</i> , 2017, 23, e385-e388.	1.0	2
48	Cerebral Venous Sinus Thrombosis Due to Low \hat{e} molecular-weight Heparin-induced Thrombocytopenia. <i>Neurologist</i> , 2017, 22, 241-244.	0.4	14
49	Spontaneous Heparin-Induced Thrombocytopenia and Venous Thromboembolism following Total Knee Arthroplasty. <i>Case Reports in Hematology</i> , 2017, 2017, 1-4.	0.3	8
50	Thrombophilic risk of individuals with rare compound factor V Leiden and prothrombin G20210A polymorphisms: an international case series of 100 individuals. <i>European Journal of Haematology</i> , 2016, 97, 353-360.	1.1	10
51	Concurrent Disseminated Nocardiosis and GI Mucormycosis in a Stem-Cell Transplantation Recipient. <i>Journal of Clinical Oncology</i> , 2016, 34, e84-e86.	0.8	7
52	Thrombin generation and cell \hat{e} dependent hypercoagulability in sickle cell disease. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 1941-1952.	1.9	53
53	Importance of pharmacokinetic studies in the management of acquired factor X deficiency. <i>European Journal of Haematology</i> , 2016, 96, 60-64.	1.1	5
54	Strategies to Improve Safety and Outcomes Utilizing Systems-Based Hematologists in IVC Filter Placement and Management in an Academic Medical Center. <i>Blood</i> , 2016, 128, 4739-4739.	0.6	1

#	ARTICLE	IF	CITATIONS
55	Thrombophilia. <i>Vascular Medicine</i> , 2015, 20, 193-196.	0.8	13
56	Lenalidomide-associated hemolytic anemia. <i>Leukemia and Lymphoma</i> , 2015, 56, 2717-2719.	0.6	2
57	Management of adult non-severe haemophilia A patients with inhibitors: a practice-pattern survey. <i>Haemophilia</i> , 2015, 21, e422-e424.	1.0	3
58	Profile of sapacitabine: potential for the treatment of newly diagnosed acute myeloid leukemia in elderly patients. <i>Clinical Interventions in Aging</i> , 2014, 9, 753.	1.3	11
59	Epstein-Barr virus reactivation and hemophagocytic lymphohistiocytosis in a patient with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2014, 55, 2938-2941.	0.6	4
60	Rituximab as first-line treatment for the management of adult patients with non-severe hemophilia A and inhibitors. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 897-901.	1.9	11
61	Red blood cells and thrombin generation in sickle cell disease. <i>Thrombosis Research</i> , 2014, 133, S52-S53.	0.8	9
62	Clinical features and management of haemophilic pseudotumours: a single US centre experience over a 30-year period. <i>Haemophilia</i> , 2014, 20, e58-62.	1.0	35
63	Self-perceptions of age among 292 chemotherapy-treated cancer patients: Exploring associations with symptoms and survival. <i>Journal of Geriatric Oncology</i> , 2013, 4, 249-254.	0.5	6
64	Comparison of complication rates of Hickman catheters versus peripherally inserted central catheters in patients with acute myeloid leukemia undergoing induction chemotherapy. <i>Leukemia and Lymphoma</i> , 2013, 54, 1263-1267.	0.6	29
65	Hemostatic abnormalities in sickle cell disease. <i>Current Opinion in Hematology</i> , 2013, 20, 472-477.	1.2	70
66	Isolated Cranial Mononeuropathy: An Unusual Initial Presentation and Disease Progression of Metastatic Carcinoma of the Breast. <i>Journal of Clinical Oncology</i> , 2013, 31, e294-e296.	0.8	2
67	Outcomes of management of acute coronary syndrome in patients with congenital bleeding disorders: A single center experience and review of the literature. <i>Thrombosis Research</i> , 2012, 130, 316-322.	0.8	24
68	65-Year-Old Woman With Shortness of Breath and Dark Urine. <i>Mayo Clinic Proceedings</i> , 2011, 86, 912-915.	1.4	2
69	Cardiovascular disease risk factors. <i>Blood Coagulation and Fibrinolysis</i> , 2011, 22, 402-406.	0.5	49
70	Impact of lifestyle modification on symptomatic coronary artery disease in a haemophilia patient with inhibitors. <i>Haemophilia</i> , 2011, 17, e1006-e1007.	1.0	3
71	Management of Acute Coronary Syndrome In Patients with An Inherited Bleeding Disorder: A Single Center Experience.. <i>Blood</i> , 2010, 116, 3660-3660.	0.6	3
72	Audit on the management of diabetes in terminally-ill medical patients. <i>Progress in Palliative Care</i> , 2009, 17, 302-306.	0.7	3